A trellis is practical for supporting plants, but it also can be beautiful and add an interesting accent to your garden's ...

Mark Kaiser and Tim Bannister joined the morning show to discuss Barb, Taryn, Gracie Trivia Night, which honors the victims ...

A pair of privately-held developers of editing-based therapies have some successes to show for their recent efforts to ...

Arbor Biotechnologies has closed $73.9m in a Series C financing round, earmarked for advancing its gene editing therapeutic ...

The firm will use the funds to develop its lead candidate in primary hyperoxaluria type 1 and other pipeline products in liver and CNS disorders.

Stoke Therapeutics CEO Ed Kaye is stepping down, the company said. He will be replaced on an interim basis by Director Ian ...

Financing extends Arbor’s cash runway into 2027 and supports the clinical development of lead program ABO-101 and continued advancement of a broader portfolio of CNS-targeted gene editing therapeutics ...

As other gene editing programs fold or get sold, Arbor Biotechnologies has secured $73.9 million to advance its lead ...

At a time when CRISPR companies have struggled, the Feng Zhang spinoff Arbor Biotechnologies gets a cash infusion to head to clinical trials.

The gene therapy world is in turmoil, but Arbor, armed with more than a billion dollars in partnerships and raises, is going forward.

Series C led by ARCH Venture Partners and TCGX with significant participation from existing and new investors Financing extends Arbor’s cash runway into 2027 and supports the clinical development of ...

The round will fund a “one-and-done” treatment for a rare kidney condition that its CEO says can address concerns patients ...